Patents by Inventor James Clifford Sutton

James Clifford Sutton has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • AhR MODULATORS
    Publication number: 20190270754
    Abstract: Provided herein are compounds, compositions and methods of using the compounds and compositions for the treatment of diseases modulated, as least in part, by AhR. The compounds are represented by formulae: wherein the letters and symbols X1, X2, Z, R1b, R1c, R1d, R1e, R2a, R2b, R2c and R2d have the meanings provided in the specification.
    Type: Application
    Filed: February 5, 2019
    Publication date: September 5, 2019
    Inventors: Muzaffar ALAM, Hilary Plake BECK, Michael Patrick DILLON, Marcos GONZALEZ-LOPEZ, James Clifford SUTTON, JR.
  • TRICYCLIC COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS
    Publication number: 20190092780
    Abstract: The present invention provides a compound of Formula (I) including pharmaceutically acceptable salts thereof: and therapeutic uses of these compounds. The invention further provides pharmaceutical compositions comprising these compounds, compositions comprising these compounds with a therapeutic co-agent, and methods of using the compounds and compositions to treat viral infections.
    Type: Application
    Filed: March 7, 2017
    Publication date: March 28, 2019
    Inventors: Rama JAIN, Dennis Christofer KOESTER, James R. MANNING, James Clifford SUTTON, Benjamin Robert TAFT, Lifeng WAN, Qian ZHAO
  • Fused tricyclic pyridazinone compounds useful to treat orthomyxovirus infections
    Patent number: 10160764
    Abstract: The invention provides compounds of Formula (I): as further described herein, as well as pharmaceutical compositions comprising such compounds, and methods to use the compounds and pharmaceutical compositions for treatment of certain viral disorders, including influenza.
    Type: Grant
    Filed: August 25, 2017
    Date of Patent: December 25, 2018
    Assignee: Novartis AG
    Inventors: Rama Jain, Dennis Christofer Koester, James R. Manning, Vanessa Marx, Daniel Poon, James Clifford Sutton, Benjamin R. Taft, Lifeng Wan, Aregahegn Yifru, Qian Zhao
  • 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant IDH
    Patent number: 10112931
    Abstract: The invention is directed to a formula (I): or a pharmaceutically acceptable salt thereof, wherein R1, R2a, R2b and R3-R7 are herein. The invention is also directed to compositions containing a compound of formula (I) and to the use of such compounds in the inhibition of mutant IDH proteins having a neomorphic activity. The invention is further directed to the use of a compound of formula (I) in the treatment of diseases or disorders associated with such mutant IDH proteins including, but not limited to, cell-proliferation disorders, such as cancer.
    Type: Grant
    Filed: April 27, 2017
    Date of Patent: October 30, 2018
    Assignee: NOVARTIS AG
    Inventors: Thomas Raymond Caferro, Zhuoliang Chen, Young Shin Cho, Abran Q. Costales, Julian Roy Levell, Gang Liu, James R. Manning, Martin Sendzik, Cynthia Shafer, Michael David Shultz, James Clifford Sutton, Yaping Wang, Qian Zhao
  • FUSED TRICYCLIC PYRIDAZINONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS
    Publication number: 20180057501
    Abstract: The invention provides compounds of Formula (I): as further described herein, as well as pharmaceutical compositions comprising such compounds, and methods to use the compounds and pharmaceutical compositions for treatment of certain viral disorders, including influenza.
    Type: Application
    Filed: August 25, 2017
    Publication date: March 1, 2018
    Inventors: Rama JAIN, Dennis Christofer KOESTER, James R. MANNING, Vanessa MARX, Daniel POON, James Clifford SUTTON, Benjamin R. TAFT, Lifeng WAN, Aregahegn YIFRU, Qian ZHAO
  • 3-PYRIMIDIN-4-YL-OXAZOLIDIN-2-ONES AS INHIBITORS OF MUTANT IDH
    Publication number: 20180051015
    Abstract: The invention is directed to a formula (I): or a pharmaceutically acceptable salt thereof, wherein R1, R2a, R2b and R3-R7 are herein. The invention is also directed to compositions containing a compound of formula (I) and to the use of such compounds in the inhibition of mutant IDH proteins having a neomorphic activity. The invention is further directed to the use of a compound of formula (I) in the treatment of diseases or disorders associated with such mutant IDH proteins including, but not limited to, cell-proliferation disorders, such as cancer.
    Type: Application
    Filed: April 27, 2017
    Publication date: February 22, 2018
    Inventors: Thomas Raymond CAFERRO, Zhuoliang CHEN, Young Shin CHO, Abran Q. COSTALES, Julian Roy LEVELL, Gang LIU, James R. MANNING, Martin SENDZIK, Cynthia SHAFER, Michael David SHULTZ, James Clifford SUTTON, Yaping WANG, Qian ZHAO
  • 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant IDH
    Patent number: 9688672
    Abstract: The invention is directed to a formula (I): or a pharmaceutically acceptable salt thereof, wherein R1, R2a, R2b and R3-R7 are herein. The invention is also directed to compositions containing a compound of formula (I) and to the use of such compounds in the inhibition of mutant IDH proteins having a neomorphic activity. The invention is further directed to the use of a compound of formula (I) in the treatment of diseases or disorders associated with such mutant IDH proteins including, but not limited to, cell-proliferation disorders, such as cancer.
    Type: Grant
    Filed: July 13, 2016
    Date of Patent: June 27, 2017
    Assignee: NOVARTIS AG
    Inventors: Thomas Raymond Caferro, Zhuoliang Chen, Young Shin Cho, Abran Q. Costales, Julian Roy Levell, Gang Liu, James R. Manning, Martin Sendzik, Cynthia Shafer, Michael David Shultz, James Clifford Sutton, Yaping Wang, Qian Zhao
  • 3-PYRIMIDIN-4-YL-OXAZOLIDIN-2-ONES AS INHIBITORS OF MUTANT IDH
    Publication number: 20160318915
    Abstract: The invention is directed to a formula (I): or a pharmaceutically acceptable salt thereof, wherein R1, R2a, R2b and R3-R7 are herein. The invention is also directed to compositions containing a compound of formula (I) and to the use of such compounds in the inhibition of mutant IDH proteins having a neomorphic activity. The invention is further directed to the use of a compound of formula (I) in the treatment of diseases or disorders associated with such mutant IDH proteins including, but not limited to, cell-proliferation disorders, such as cancer.
    Type: Application
    Filed: July 13, 2016
    Publication date: November 3, 2016
    Applicant: NOVARTIS AG
    Inventors: Thomas Raymond CAFERRO, Zhuoliang CHEN, Young Shin CHO, Abran Q. COSTALES, Julian Roy LEVELL, Gang LIU, James R. MANNING, Martin SENDZIK, Cynthia SHAFER, Michael David SHULTZ, James Clifford SUTTON, Yaping WANG, Qian ZHAO
  • 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant IDH
    Patent number: 8957068
    Abstract: The invention is directed to a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein R1-R6 are defined herein. The invention is also directed to compositions containing a compound of formula (I) and to the use of such compounds in the inhibition of mutant IDH proteins having a neomorphic activity. The invention is further directed to the use of a compound of formula (I) in the treatment of diseases or disorders associated with such mutant IDH proteins including, but not limited to, cell-proliferation disorders, such as cancer.
    Type: Grant
    Filed: September 26, 2012
    Date of Patent: February 17, 2015
    Assignee: Novartis AG
    Inventors: Thomas Raymond Caferro, Young Shin Cho, Abran Q. Costales, Huangshu Lei, Francois Lenoir, Julian Roy Levell, Gang Liu, Mark G. Palermo, Keith Bruce Pfister, Martin Sendzik, Cynthia Shafer, Michael David Shultz, Troy Smith, James Clifford Sutton, Bakary-Barry Toure, Fan Yang, Qian Zhao
  • 3-PYRIMIDIN-4-YL-OXAZOLIDIN-2-ONES AS INHIBITORS OF MUTANT IDH
    Publication number: 20140235620
    Abstract: The invention is directed to a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein R1-R6 are defined herein. The invention is also directed to compositions containing a compound of formula (I) and to the use of such compounds in the inhibition of mutant IDH proteins having a neomorphic activity. The invention is further directed to the use of a compound of formula (I) in the treatment of diseases or disorders associated with such mutant IDH proteins including, but not limited to, cell-proliferation disorders, such as cancer.
    Type: Application
    Filed: September 26, 2012
    Publication date: August 21, 2014
    Applicant: NOVARTIS AG
    Inventors: Thomas Raymond Caferro, Young Shin Cho, Abran Q. Costales, Huangshu Lei, Francois Lenoir, Julian Roy Levell, Gang Liu, Mark G. Palermo, Keith Bruce Pfister, Martin Sendzik, Cynthia Shafer, Michael David Shultz, Troy Smith, James Clifford Sutton, Bakary-Barry Toure, Fan Yang, Qian Zhao